IMS Health to acquire SDI

Share this article:

IMS Health will acquire SDI, bringing two of the largest data firms servicing the pharmaceutical industry together into one company. Financial terms of the deal were not disclosed.

Both companies declined to discuss the acquisition beyond a joint statement released last Friday afternoon. Unnamed company sources told Ed Silverman, who first reported the deal on his Pharmalot blog, that as much as 15% of SDI's staff could lose their jobs as a result of the acquisition.

“The addition of SDI's complementary information assets and capabilities positions IMS to improve existing offerings, fuel new investments and deliver greater innovation and value to a healthcare industry that is seeking to drive increased efficiencies as a result of significant, ongoing pressure to reduce costs and expand patient access,” the joint statement said.

Gary Gatyas, an IMS Health spokesperson, declined to speculate on timing for the completion of the deal, citing pre-merger notification requirements with respect to the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

SDI acquired Verispan in 2008, tripling its size in terms of workforce. Wolters Kluwer and Kantar Health were not immediately available to comment on ramifications of the acquisition.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...